Management of spasticity in children with cerebral palsy

Acta Orthopaedica et Traumatologica Turcica

Volumn 43, Issue 2, 2009, Pages 81-86

  Matthews, Dennis J ^a   Balaban, Birol ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Baclofen; Botulinum toxin type A; Cerebral palsy drug therapy surgery; Child; Dantrolene; Injections, spinal; Movement disorders; Muscle spasticity drug therapy; Rhizotomy

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANTIPARKINSON AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CENTRAL MUSCLE RELAXANT; DANTROLENE; PHENOL;

ARTICLE; CEREBRAL PALSY; CHEMICAL SYMPATHECTOMY; CHILD; EVIDENCE BASED MEDICINE; HUMAN; INTRASPINAL DRUG ADMINISTRATION; METHODOLOGY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PATIENT CARE; RHIZOTOMY; SPASTICITY;

ADMINISTRATION, ORAL; ANTI-DYSKINESIA AGENTS; BACLOFEN; BENZODIAZEPINES; BOTULINUM TOXINS; CEREBRAL PALSY; CHILD; DANTROLENE; EVIDENCE-BASED MEDICINE; GABA AGONISTS; HUMANS; INJECTIONS, SPINAL; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; PATIENT-CENTERED CARE; PHENOL; RHIZOTOMY; SYMPATHECTOMY, CHEMICAL;

EID: 67650136670     PISSN: 1017995X     EISSN: None     Source Type: Journal    
DOI: 10.3944/AOTT.2009.081     Document Type: Article

References (53)

1. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, et al. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 2005;47:571-6.
2. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW; Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003;111:e89-97.
3. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disorder of motor control. Chicago: Year Book Medical Publishers; 1980. p. 485-94.
4. Massagli TL. Spasticity and its management in children. Phys Med Rehabil Clin N Am 1991;2:867-89.
5. Katz RT. Management of spastic hypertonia after stroke. J Neurol Rehabil 1991;5(Suppl 1):S5-S12.
6. Krach LE. Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. J Child Neurol 2001;16:31-6.
7. Edgar TS. Oral pharmacotherapy of childhood movement disorders. J Child Neurol 2003;18 Suppl 1:S40-9.
8. Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977;5:398-404.
9. McKinlay I, Hyde E, Gordon N. Baclofen: a team approach to drug evaluation of spasticity in childhood. Scott Med J 1980;S26-8.
10. Gracies JM, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part I: Local treatments. Muscle Nerve Suppl 1997;6:S61-91.
11. Nance PW, Young RR. Antispasticity medications. Phys Med Rehabil Clin N Am 1999;10:337-55.
12. Badell A. The effects of medications that reduce spasticity in the management of spastic cerebral palsy. J Neuro Rehab 1991;5(Suppl 1):S13-S14.
13. Nance P, Meythaler JM. Spasticity management. In: Braddom RL, editor. Physical medicine and rehabilitation, 3rd ed. Philadelphia: Saunders Elsevier; 2006. p. 651-66.
14. Halpern D, Meelhuysen FE. Phenol motor point block in the management of muscular hypertonia. Arch Phys Med Rehabil 1966;47:659-64.
15. Sung DH, Han TR, Park WH, Je Bang H, Kim JM, Chung SH, et al. Phenol block of peripheral nerve conduction: Titrating for optimum effect. Arch Phys Med Rehabil 2001; 82:671-6.
16. Easton JK, Ozel T, Halpern D. Intramuscular neurolysis for spasticity in children. Arch Phys Med Rehabil 1979; 60:155-8.
17. Halpern D, Meelhuysen FE. Duration of relaxation after intramuscular neurolysis with phenol. JAMA 1967;200: 1152-4.
18. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994;36:386-96.
19. Graham HK, Aoki KR, Autti-Rämö I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11:67-79.
20. Boyd RN, Hays RM. Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 2001;8 Suppl 5:1-20.
21. Jefferson RJ. Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol 2004;46:491-9.
22. Yang TF, Fu CP, Kao NT, Chan RC, Chen SJ. Wei TS. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. Am J Phys Med Rehabil 2003; 82:284-9.
23. Hurvitz EA, Conti GE, Brown SH. Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection. Arch Phys Med Rehabil 2003;84:444-54.
24. Russman BS, Tilton A, Gormley ME Jr. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl 1997;6: S181-93.
25. Gaebler-Spira D, Revivo G. The use of botulinum toxin in pediatric disorders. Phys Med Rehabil Clin N Am 2003; 14:703-25.
26. Kinnett D. Botulinum toxin A injections in children: technique and dosing issues. Am J Phys Med Rehabil 2004; 83(10 Suppl):S59-64.
27. Goldstein EM. Spasticity management: an overview. J Child Neurol 2001;16:16-23.
28. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-8.
29. Bottos M, Benedetti MG, Salucci P, Gasparroni V, Giannini S. Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment. Dev Med Child Neurol 2003;45:758-62.
30. Kay RM, Rethlefsen SA, Fern-Buneo A, Wren TA, Skaggs DL. Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy. J Bone Joint Surg [Am] 2004;86:2377-84.
31. Koman LA, Mooney JF 3rd, Smith BP, Walker F, Leon JM. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000;20: 108-15.
32. Thompson NS, Baker RJ, Cosgrove AP, Corry IS, Graham HK. Musculoskeletal modelling in determining the effect of botulinum toxin on the hamstrings of patients with crouch gait. Dev Med Child Neurol 1998;40:622-5.
33. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 1998;18:304-11.
34. Desloovere K, Molenaers G, Jonkers I, De Cat J, De Borre L, Nijs J, et al. A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol 2001;8 Suppl 5:75-87.
35. Mall V, Heinen F, Siebel A, Bertram C, Hafkemeyer U, Wissel J, et al. Treatment of adductor spasticity with BTXA in children with CP: a randomized, double-blind, placebo controlled study. Dev Med Child Neurol 2006;48:10-3.
36. Barwood S, Baillieu C, Boyd R, Brereton K, Low J, Nattrass G, et al. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol 2000;42:116-21.
37. Crowner BE, Brunstrom JE, Racette BA. Iatrogenic botulism due to therapeutic botulinum toxin A injection in a pediatric patient. Clin Neuropharmacol 2007;30:310-3.
38. Howell K, Selber P, Graham HK, Reddihough D. Botulinum neurotoxin A: an unusual systemic effect. J Paediatr Child Health 2007;43:499-501.
39. Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996;11:77-83.
40. Verrotti A, Greco R, Spalice A, Chiarelli F, Iannetti P. Pharmacotherapy of spasticity in children with cerebral palsy. Pediatr Neurol 2006;34:1-6.
41. Gilmartin R, Bruce D, Storrs BB, Abbott R, Krach L, Ward J, et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 2000;15:71-7.
42. Green LB, Hurvitz EA. Cerebral palsy. Phys Med Rehabil Clin N Am 2007;18:859-82.
43. Duhon BS, MacDonald JD. Infusion of intrathecal baclofen for acute withdrawal. Technical note. J Neurosurg 2007; 107:878-80.
44. Meythaler JM, Roper JF, Brunner RC. Cyproheptadine for intrathecal baclofen withdrawal. Arch Phys Med Rehabil 2003;84:638-42.
45. Armstrong RW, Steinbok P, Cochrane DD, Kube SD, Fife SE, Farrell K. Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. J Neurosurg 1997;87:409-14.
46. Krach LE, Kriel RL, Gilmartin RC, Swift DM, Storrs BB, Abbott R, et al. GMFM 1 year after continuous intrathecal baclofen infusion. Pediatr Rehabil 2005;8:207-13.
47. Bjornson KF, McLaughlin JF, Loeser JD, Nowak-Cooperman KM, Russel M, Bader KA, et al. Oral motor, communication, and nutritional status of children during intrathecal baclofen therapy: a descriptive pilot study. Arch Phys Med Rehabil 2003;84:500-6.
48. McCoy AA, Fox MA, Schaubel DE, Ayyangar RN. Weight gain in children with hypertonia of cerebral origin receiving intrathecal baclofen therapy. Arch Phys Med Rehabil 2006;87:1503-8.
49. Park TS. Selective dorsal rhizotomy for the spasticity of cerebral palsy. In: Rengachery SS, Wilkins RH, editors. Neurosurgical operative atlas. Park Ridge, IL: American Association of Neurological Surgeons; 1994. p. 183-90.
50. Engsberg JR, Ross SA, Collins DR, Park TS. Predicting functional change from preintervention measures in selective dorsal rhizotomy. J Neurosurg 2007;106(4 Suppl):282-7.
51. McLaughlin J, Bjornson K, Temkin N, Steinbok P, Wright V, Reiner A, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol 2002;44:17-25.
52. Engsberg JR, Ross SA, Collins DR, Park TS. Effect of selective dorsal rhizotomy in the treatment of children with cerebral palsy. J Neurosurg 2006;105(1 Suppl):8-15.
53. Steinbok P, Schrag C. Complications after selective posterior rhizotomy for spasticity in children with cerebral palsy. Pediatr Neurosurg 1998;28:300-13.